Briefing documents released ahead of Thursday’s FDA advisory committee meeting regarding Vanda Pharmaceuticals Inc.’s therapy for non-24-hour disorder, tasimelteon, revealed an ongoing disconnect between the sponsor and agency regarding clinical endpoints for the disorder, whose symptoms can be difficult to pin down.